Mozobil

Phase 2Small molecule

NNational Institute of Allergy and Infectious Diseases (NIAID)

Mozobil is one of 10 small molecule programs targeting Beta-Thalassemia Major. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Beta-Thalassemia MajorActive, not recruiting

Stem CellsRecruiting

Beta-Thalassemia MajorPreclinical

Active, not recruiting

Stem CellsPhase 2

Recruiting

Competition

Competitive Landscape

7 competitors in Stem Cells

#DrugCompanyPhaseTrials

Mozobil

GGenzyme, a Sanofi Company

Phase 2

5 2

Advil

KKenvue Brands

Phase 2

1 3

G-CSF

AArog Pharmaceuticals, Inc.

Phase 1

1 4

Mozobil

NNational Institute of Allergy and Infectious Diseases (NIAID)

Phase 2

1 5

Blood

UUniversity Hospital, Lille

Preclinical

1 6

Adipose-Derived Stem Cells

XXuzhou Medical University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Stem Cells1 trial

Combination of Ibuprofen, G-CSF and Plerixafor as Stem Cells Mobilization Regimen in Patients Affected by X-CGD

Recruiting·IIRCCS San Raffaele·Phase 2·NCT03055247·3 enrolled

Multiple Myeloma1 trial

Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)

Completed·SSiddhartha Ganguly·Phase 2·NCT02703779·101 enrolled

Radiotherapy1 trial

A Dose Finding Study of CycloSam® Combined With External Beam Radiotherapy

Withdrawn·—·Phase 1·NCT03612466

Beta-Thalassemia Major1 trial

Evaluating the Safety and Effectiveness of Mozobil Mobilization in Adults With Beta-Thalassemia Major

Completed·UUniversity of Washington·N/A·NCT01206075·20 enrolled

Stem Cell1 trial

Stem Cell Mobilization With Plerixafor in Diabetic vs Control Subjects

Completed·UUniversity of Padova·Phase 4·NCT02056210·20 enrolled

1 more indication

Leukopenia1 trial

A Phase I Study of MozobilTM in the Treatment of Patients With WHIMS

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Preclinical·NCT00967785·14 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Mozobil. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mozobil compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mozobil. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Institute of Allergy and Infectious Diseases (NIAID) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNational Institute of Allergy and Infectious Diseases (NIAID)

Mozobil

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Stem Cells1 trial

Multiple Myeloma1 trial

Radiotherapy1 trial

Beta-Thalassemia Major1 trial

Stem Cell1 trial

Leukopenia1 trial

References

Drug Info

Quick Facts

Related News